Electroceuticals, also known as bioelectrical is a term used to describe miniature devices which can alter electrical signals diffused by nerves throughout the body to treat a wide range of illnesses unlike other stimulators of muscles and tissues. The unique value of electroceuticals is derived from the fact that they can have a much-localized action and act much faster with lesser side effects as compared to conventional drugs or chemical-based pharmaceuticals that alter molecular pathways. Although, as of now, the focus of electroceuticals development is on conditions where drugs are ineffective or have considerable side effects, the strong efficacy and cost-effectiveness of the electroceuticals benefits might be set to disrupt the pharmaceutical industry sooner than later by replacing standard drug care therapy.
The global electroceuticals market is expected to grow at a CAGR of xx% during 2017 to 2025 to reach US$xx billion by 2025 from an estimated market value US$xx billion in 2016. The electroceuticals market growth is due to rising geriatric population, regulatory approval for new and advanced electroceuticals, growing investments by big pharma companies and funds by government and universities for the development of novel therapies and electroceuticals, advancement in technology such as miniaturization, improved battery technology, advent of wearable devices, wireless micro-current stimulation, rising prevalence of neurological disorders and hearing loss and increasing chronic pain market with unmet needs for alternate therapies for Opioids use.
The electroceutical devices global market is categorized into invasive and non-invasive electroceutical devices based on the mechanism of action. The invasive or internal electroceutical segment held the largest market revenue in 2015 and is expected to grow at a higher growth rate from 2015 to 2022 as compared to external or non-invasive electroceuticals due to technological advancement in wireless microcurrent stimulation, wearable pain management technology, miniaturization etc.
North America accounts for the highest market share followed by Europe and will continue to lead the market in the coming years. The large share of the North American region can be attributed to the rising prevalence of heart diseases, chronic diseases and increasing regulatory approvals of electroceutical devices. Moreover, the shift in preference toward these devices by patients and healthcare providers who are resistant towards the conventional techniques like surgeries and drug therapy will also contribute to this market’s growth in the region.
Key questions answered and insights delivered in the report:
- What is electroceuticals market size by value from 2015-2025?
- What was the electroceuticals market size by product types in 2015?
- What is the neurostimulation market size by value from 2012-2025?
- What is the cardiac pacemaker market size by value and volume from 2015-2025?
- What is the ICD market size by value and volume from 2011-2025?
- What is the spinal cord stimulators market size by value from 2012-2025?
- What is the sacral nerve stimulators market size by value from 2012-2025?
- What is the cochlear implants market size by value and volume from 2012-2025?
- What is the deep brain stimulators market size by value 2012-2025?
- What is the vagus nerve stimulators market size by value 2012-2025?
- What was North America electroceuticals market size by products 2016?
- A comprehensive mapping of competitive landscape of key players and their electroceutical products in different therapy areas.
- Mergers & Acquisitions, collaborations and other strategies adopted by the key players in the market.
- A comprehensive analysis of recently launched electroceuticals products.
- Pipeline analysis of key players by therapy area.
1. Electroceuticals: An Introduction
2. Types of Electroceuticals
I. Cardiac Electrostimulation
II. Classification of Stents
a. Cardiac Pacemakers
b. Implantable Cardioverter defibrillator
II. Invasive Neurostimulation
a. Spinal Cord Stimulation (SCS) or Peripheral Nerve Stimulation (PNS):
b. Deep Brain Stimulation (DBS)
c. Motor Cortex Stimulation (MCS)
d. Occipital Nerve Stimulation (ONS) 16
III. Non-invasive Neurostimulation Categories:
a. Transcutaneous Electrical Nerve Stimulation (TENS)
b. Repetitive Transcranial Magnetic Stimulation (rTMS)
c. Transcranial Direct Current Stimulation (tDCS)
IV. Cochlear Implants
V. Retinal Implants
3. Application of Electroceuticals
I. Current & Marketed Applications
II. Future Applications of Electroceuticals
4. Global Electroceuticals Market: An Analysis
I. Global Electroceuticals Market by Value
II. Global Electroceutical Market Share by Application Areas
a. Global Neurostimulation Market by Value
b. Global Cardiac Pacemaker Market
c. Global ICD Market
d. Global Spinal Cord Stimulators Market
e. Global Sacral Nerve Stimulators Market
f. Global Cochlear Implants Market
g. Global Deep Brain Stimulators Market
h. Global Vagus Nerve Stimulators Market
III. Electroceutical Market by Regions
a. North America Electroceutical Market
5. Competitive Landscape
I. M&A Activity in Electroceuticals Market
II. Key Product Analysis
6. Patent & Technology Landscape
I. Methodology
7. Product Pipeline Analysis
8. Growth Drivers
I. Expansion in Research and Development (R&D)
II. Increasing Ageing Population 58
III. Rise in Prevalence of Chronic Diseases
9. Trends and Developments
I. Technological Advancements
II. Launch of Electrical Prescriptions (ElectRx) Program
III. Brain Imaging - Invention of New Biomarkers in PTSD
IV. Accelerating Dementia Drug Discovery
V. Introduction of “Ultrasonic Neural Dust”
VI. Introduction of “Ultrasonic Neural Dust”
10. Challenges
I. Miniaturization & Personalization of Devices
II. Complex Manufacturing Process
III. Lack of Detailed Knowledge of Biology of Neural Pathways
11. Company Profiles:
I. Medtronic
a. Business Overview
b. Electroceuticals Product Portfolio
c. Business Strategy
II. EnteroMedics
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
III. Allergan PLC
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
IV. Brainsway
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
V. Advanced Bionics
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
VI. Labyrinth Devices, LLC
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
VII. Second Sight Medical Products, Inc.
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
VIII. ElectroCore LLC
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
IX. Vomaris Wound Care, Inc.
a. Business Overview
b. Electroceuticals Product
c. Business Strategy
X. Bioelectric Research
Figure 4.2 Global Electroceutical Market Share by application areas (2016)
Figure 4.3 Global Neurostimulation Market by Value (2012-2025)
Figure 4.4 Global Cardiac Pacemaker Market by Value and Volume (2015-2025)
Figure 4.5 Global ICD Market by Value & Volume (2011-2025)
Figure 4.8 Global Cochlear Implants Market by Value and Volume (2012-2025)
Figure 4.9 Global Deep Brain Stimulators Market by Value (2012-2025)
Figure 4.10: Global Vagus Nerve Stimulators Market by Value (2012-2025)
Figure 4.11 North America Electroceutical Market Share by Segments (2016)
Figure 5.1: Application of Electroceuticals by Therapy Area (2016)
Figure 6.1: Patent publication trend (2013-2017)
Figure 6.2: Country-wise patenting activity
Figure 6.3: Key players based on patenting activity
Figure 8.1: R&D Investment in Electroceuticals Market by Companies (2016)
Figure 8.2: Global Ageing Population (2000-2050)
Figure 8.3: Prevalence of Chronic Disease in the US (2000-2030)
Figure 11.1: Medtronic Net Sales Share by Business Segments (2016)
Figure 11.2: Medtronic Net Sales Share by Region (2016)
Figure 11.3: Net Sales and Net Income (2013-2017)
Figure 11.4: Research & Development expenses (2013-2017)
Figure 11.5 EnteroMedics Research & Development Expenses (2011-2015)
Figure 11.6: Allergan PLC Revenue Share by Business Segments (2016)
Figure 11.6: Allergan PLC Net Revenue and Net Income (2012-2016)
Figure 11.7: Allergan PLC Research & Development Expenses (2012-2016)
Figure 11.8: Brainsway Net Revenues (2013-2016)
Figure 11.9: Brainsway Research & Development Expenses (2013-2016)
Figure 11.10: Second Sight Medical Net Sales (2012-2016)
Figure 11.11: Second Sight Medical Research & Development Expenses (2012-2016)
Figure 11.12: LivaNova PLC Revenue Share by Business Segments (2016)
Figure 11.13: LivaNova PLC Revenue Share by Region (2016)
Figure 11.14: LivaNova PLC Net Sales and Net Income (2012-2016)
Figure 11.15: LivaNova PLC Research & Development Expenses (2012-2016)
Figure 11.16: Cochlear Ltd Net Sales and Net Income (2012-2016)
Figure 11.17: Cochlear Ltd Research & Development Expenses (2012-2016)
Figure 11.18: St. Jude Medical Net Sales and Net Income (2011-2015)
Figure 11.19: St. Jude Medical Research & Development Expenses (2011-2015)
Figure 11.20: NeuroMetrix Net Sales and Net Income (2012-2016)
Figure 11.21: NeuroMetrix Research & Development Expenses (2012-2016)
Figure 11.22: Nevro Corporation Revenue (2012-2016)
Figure 11.23: Nevro Corporation Research & Development Expenses (2012-2016)
Table 1: Current Applications of Electroceuticals
Table 2: Future Applications of Electroceuticals
Table 3: Competitive Landscape of Key Players (2016)
Table 4: Presence of Companies in Key Therapy Areas (2016)
Table 5: Joint Ventures, Mergers & Acquisitions in Electroceuticals Market
Table 6: Product Analysis of Key Players
Table 7: Time-wise patenting activity of key players
Table 10: Pipeline Products by Therapy Area